Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Brilacidin is easier to value since there are studies that compared it with drugs currently on the market. But, there are also 2 B versions where there is no effective treatment, only market estimates. If B is great, highly effective against UP and OM, plus what we know of ABSSSI, those 3 alone would be expected to generate annual sales of about $1 billion each by the 3rd year on the market. Using a very conservative 3 times potential sales as a benchmark, the cap can be expected to settle in above $9 billion. 180 million shares fully diluted works out to about $50 a share, just for Brilacidin and its 3 lead indications.